MedTrace Logo

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-10-02

No results posted yet for this study

Summary

Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being independent at 6 months. There is currently no approved treatment for ICH which has been shown to improve outcomes. In an effort to develop a new treatment for ICH, this research focuses on a different aspect of ICH treatment which has not yet been evaluated: enhancing absorption of the blood clot with medication.

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

Pioglitazone

Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI

DRUG

Placebo Control

Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Nicole R Gonzales, MD · University of Texas Medical School-Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2013-04-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827892 on ClinicalTrials.gov